Ana Pina

Dr. Ana Pina

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2020 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
APAna Pina
Ana Pina
SHSaga Helgadottir
Saga Helgadottir
RMRosellina Margherita Mancina
Rosellina Margherita Mancina
CPChiara Pavanello
Chiara Pavanello
CPCarlo Pirazzi
Carlo Pirazzi
SRStefano Romeo
Stefano Romeo
Familial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism. The gold standard for FH diagnosis is genetic testing, available, however, only in selected university hospitals. Clinical scores – for example, the Dutch Lipid Score – are often employed as alternative, more accessible, albeit less accurate FH diagnostic tools. The aim of this study is to obtain a more reliable approach to FH diagnosis by a “virtual” genetic test using machine-learning approaches. We used three machine-learning algorithms (a classification tree (CT), a gradient boosting machine (GBM), a neural network (NN)) to predict the presence of FH-causative genetic mutations in two independent FH cohorts: the FH Gothenburg cohort (split into training data (N = 174) and internal test (N = 74)) and the FH-CEGP Milan cohort (external test, N = 364). By evaluating their area under the receiver operating characteristic (AUROC) curves, we found that the three machine-learning algorithms performed better (AUROC 0.79 (CT), 0.83 (GBM), and 0.83 (NN) on the Gothenburg cohort, and 0.70 (CT), 0.78 (GBM), and 0.76 (NN) on the Milan cohort) than the clinical Dutch Lipid Score (AUROC 0.68 and 0.64 on the Gothenburg and Milan cohorts, respectively) in predicting carriers of FH-causative mutations. In the diagnosis of FH-causative genetic mutations, all three machine-learning approaches we have tested outperform the Dutch Lipid Score, which is the clinical standard. We expect these machine-learning algorithms to provide the tools to implement a virtual genetic test of FH. These tools might prove particularly important for lipid clinics without access to genetic testing.

5 November 2022 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
APAna Pina
Ana Pina
Maria João MenesesMaria João Meneses
Maria João Meneses
ILINES SOUSA LIMA
INES SOUSA LIMA
Roberto HenriquesRoberto Henriques
Roberto Henriques
JRJOÃO FILIPE RAPOSO
JOÃO FILIPE RAPOSO
MMMaria Paula Macedo
Maria Paula Macedo
Background: Type 2 Diabetes (T2D) diagnosis is based solely on glycaemia, even though it is an endpoint of numerous dysmetabolic pathways. Type 2 Diabetes complexity is challenging in a real‐world scenario; thus, dissecting T2D heterogeneity is a priority. Cluster analysis, which identifies natural clusters within multidimensional data based on similarity measures, poses a promising tool to unravel Diabetes complexity.Methods: In this review, we scrutinize and integrate the results obtained in most of the works up to date on cluster analysis and T2D.Results: To correctly stratify subjects and to differentiate and individualize a preventive or therapeutic approach to Diabetes management, cluster analysis should be informed with more parameters than the traditional ones, such as etiological factors, pathophysiological mechanisms, other dysmetabolic co‐morbidities, and biochemical factors, that is the millieu. Ultimately, the above‐mentioned factors may impact on Diabetes and its complications. Lastly, we propose another theoretical model, which we named the Integrative Model. We differentiate three types of components: etiological factors, mechanisms and millieu. Each component encompasses several factors to be projected in separate 2D planes allowing an holistic interpretation of the individual pathology.Conclusion: Fully profiling the individuals, considering genomic and environmental factors, and exposure time, will allow the drive to precision medicine and prevention of complications.

1 September 2022 in Liver International
Verified
Journal Article
Closed access
APAna Pina
Ana Pina
Maria João MenesesMaria João Meneses
Maria João Meneses
RRRogério T. Ribeiro
Rogério T. Ribeiro
JRJOÃO FILIPE RAPOSO
JOÃO FILIPE RAPOSO
MMMaria Paula Macedo
Maria Paula Macedo

10 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
APAna Pina
Ana Pina
RPRita Patarrão
Rita Patarrão
RRRogério T. Ribeiro
Rogério T. Ribeiro
CPCarlos Penha-Goncalves
Carlos Penha-Goncalves
JRJOÃO FILIPE RAPOSO
JOÃO FILIPE RAPOSO
MMMaria Paula Macedo
Maria Paula Macedo
Type 2 diabetes (T2D) heterogeneity is a major determinant of complications risk and treatment response. Using cluster analysis, we aimed to stratify glycemia within metabolic multidimensionality and extract pathophysiological insights out of metabolic profiling. We performed a cluster analysis to stratify 974 subjects (PREVADIAB2 cohort) with normoglycemia, prediabetes, or non-treated diabetes. The algorithm was informed by age, anthropometry, and metabolic milieu (glucose, insulin, C-peptide, and free fatty acid (FFA) levels during the oral glucose tolerance test OGTT). For cluster profiling, we additionally used indexes of metabolism mechanisms (e.g., tissue-specific insulin resistance, insulin clearance, and insulin secretion), non-alcoholic fatty liver disease (NAFLD), and glomerular filtration rate (GFR). We found prominent heterogeneity within two optimal clusters, mainly representing normometabolism (Cluster-I) or insulin resistance and NAFLD (Cluster-II), at higher granularity. This was illustrated by sub-clusters showing similar NAFLD prevalence but differentiated by glycemia, FFA, and GFR (Cluster-II). Sub-clusters with similar glycemia and FFA showed dissimilar insulin clearance and secretion (Cluster-I). This work reveals that T2D heterogeneity can be captured by a thorough metabolic milieu and mechanisms profiling—metabolic footprint. It is expected that deeper phenotyping and increased pathophysiology knowledge will allow to identify subject’s multidimensional profile, predict their progression, and treat them towards precision medicine.

25 September 2019
Verified
Book Chapter
Closed access
PDF file
APAna Pina
Ana Pina
MMMaria Paula Macedo
Maria Paula Macedo
RHRoberto Henriques
Roberto Henriques

4 November 2022 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
ACAgostino Di Ciaula
Agostino Di Ciaula
HSHarshitha Shanmugam
Harshitha Shanmugam
RRRogério Ribeiro
Rogério Ribeiro
APAna Pina
Ana Pina
RARita Andrade
Rita Andrade
Piero PortincasaPiero Portincasa
Piero Portincasa